Bristol-Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)-- The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of 33 cents ($0.33) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on August 1, 2011, to stockholders of record at the close of business on July 1, 2011.

The Directors also declared a quarterly dividend of 50 cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable September 1, 2011, to stockholders of record at the close of business on August 5, 2011.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.